🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesGLP-1 and uric acid reduction — gout prevention implications Page 2

GLP-1 and uric acid reduction — gout prevention implications

Dr.RheumBOS Thu, Jun 4, 2026 at 10:10 AM 19 replies 361 viewsPage 2 of 4
BiostatsBrad
Member
456
2,345
Jul 2024
Durham, NC
Jun 4, 2026 at 11:03 AM#6
Dr.RheumBOS said:
HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 23 → 15 → 6 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

8 3LindaRN_retired, tommy_boulder, hyun_seoul and 5 others
Reply Quote Save Share Report
gary_naperville
Member
245
1,123
Oct 2024
Naperville, IL
Jun 4, 2026 at 11:23 AM#7

Following on from sarah_TO — and this may be the naive question:

How long did you give it before you decided it was working?

7 2DoseLogDan, SleepFixSam, PurityPaulOR and 4 others
Reply Quote Save Share Report
Dr.LeslieOBGYN
Member
567
2,567
May 2024
Dallas, TX
Jun 4, 2026 at 11:44 AM#8
BiostatsBrad said:
Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction…

Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:

BiomarkerAssociationEvidence Level
Baseline BMIHigher BMI → greater absolute weight lossStrong
Fasting insulinHigher insulin → better responseModerate
GLP1R gene variantsrs6923761 → variable responsePreliminary
Baseline hsCRPHigher CRP → greater CV benefitModerate
Early weight loss (4 wk)≥3% at 4 wks → strong predictor of ≥10% at 68 wksStrong

The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.

6 1james_edin, FranDenver, Dr.BariatricHTX and 3 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.RheumBOS
Member
567
2,345
Apr 2024
Boston, MA
Jun 4, 2026 at 12:05 PM#9
BiostatsBrad said:
Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction…

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 40% to 22%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

Last edited: Jun 4, 2026 at 6:05 PM
5 0lori_vegas, Dr.PulmRoch, maya_sedona and 2 others
Reply Quote Save Share Report
denise_HTX
Member
145
678
Jan 2025
Houston, TX
Jun 4, 2026 at 1:44 PM#10
Dr.LeslieOBGYN said:
Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include: Biomarker Association…

My labs after 9 months on glycaemic control: A1C 5.6%, fasting glucose 81 mg/dL, fasting insulin 4 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 7.7% and fasting glucose was 116 mg/dL. The improvement has been dramatic and consistent.

3 3TirzTom, TrialTracker_MD, JennaRN
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register